Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway
Rhea-AI Filing Summary
Instil Bio, Inc. reported second quarter 2026 results, highlighting a strong cash position and much lower operating costs while it evaluates potential acquisitions and in-licensing opportunities for novel therapeutics. As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $69.9 million, down from $76.3 million at December 31, 2025, and are expected to fund the current operating plan beyond 2027.
Operating expenses for the quarter fell to $5.6 million from $23.4 million a year earlier, driven by in-process R&D dropping to nil, research and development declining to $0.3 million, and restructuring and impairment charges falling sharply. General and administrative expense also decreased to $5.1 million. Net loss for the quarter narrowed to $4.3 million, or $0.63 per share, compared with $21.4 million, or $3.24 per share, in the prior-year quarter. On a non-GAAP basis, which excludes non-cash stock-based compensation and restructuring and impairment charges, quarterly net loss improved to $3.1 million, or $0.45 per share, versus $19.0 million, or $2.88 per share, a year earlier.
Positive
- Net loss sharply reduced year over year to $4.3 million in Q2 2026 from $21.4 million in Q2 2025, with non-GAAP net loss improving to $3.1 million from $19.0 million.
- Operating expenses significantly lower, falling to $5.6 million in Q2 2026 from $23.4 million a year earlier, including in-process R&D dropping to nil and large declines in restructuring and impairment charges.
- Cash runway extends beyond 2027, with $69.9 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 expected to fund the current operating plan beyond 2027.
Negative
- Company remains loss-making, reporting a GAAP net loss of $4.3 million and non-GAAP net loss of $3.1 million for Q2 2026, indicating continued cash burn despite lower expenses.
Filing Explained
No acquisition or licensing commitment is disclosed, so the update creates no stated transaction-related issuance or dilution for existing holders.
This Form 8-K furnishes Instil Bio’s second-quarter 2026 results and corporate update under Item 2.02; it does not disclose a completed acquisition, license, or other transaction.
The company says it is evaluating potential acquisitions, in-licensing, and related opportunities, so existing holders have no disclosed transaction-related obligation, issuance, or dilution at this stage.
As of
The 8-K states that the information and press release are furnished, not filed for Section 18 purposes, and are not incorporated by reference unless expressly stated; a later filing or announced transaction would establish whether the evaluation produces binding terms or holder-level effects.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash & securities: $69.9 million
Total operating expenses Q2 2026: $5.6 million
Net loss Q2 2026: $4.3 million
+5 more
8 metrics
Cash & securities
$69.9 million
Cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026
Total operating expenses Q2 2026
$5.6 million
Total operating expenses for the three months ended June 30, 2026
Net loss Q2 2026
$4.3 million
Net loss for the three months ended June 30, 2026
Net loss per share Q2 2026
$0.63
Basic and diluted net loss per share for the three months ended June 30, 2026
Non-GAAP net loss Q2 2026
$3.1 million
Non-GAAP net loss for the three months ended June 30, 2026
Non-GAAP EPS Q2 2026
$0.45
Non-GAAP net loss per share, basic and diluted, for the three months ended June 30, 2026
Total assets June 30, 2026
$197.7 million
Total assets on the condensed consolidated balance sheet as of June 30, 2026
Total stockholders’ equity June 30, 2026
$107.4 million
Total stockholders’ equity as of June 30, 2026
Key Terms
non-GAAP net loss, in-process research and development, restructuring and impairment charges, net, cash equivalents, +1 more
5 terms
non-GAAP net loss financial
"These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share"
Non-GAAP net loss is a company’s reported loss that has been adjusted by removing certain costs or one-time items that the company believes hide its core operating performance. Think of it like looking at a household budget but excluding an unusual repair or sale; it can show a clearer view of everyday results, which helps investors judge ongoing profitability, but it can also omit real expenses so it should be compared with the standard GAAP loss.
in-process research and development financial
"In-process research and development expenses were nil for the three and six months"
Unfinished research and development work—such as drug candidates, prototypes, or process designs—that a company is actively developing but has not yet completed or commercialized. Investors care because it represents potential future products or technologies (like a half-built prototype) whose value is uncertain; it affects how acquisitions are priced, how future profits and costs are forecast, and can be written down if the project fails.
restructuring and impairment charges, net financial
"Restructuring and impairment charges, net were $0.2 million and $1.2 million"
cash equivalents financial
"cash, cash equivalents, restricted cash and marketable securities of $69.9 million"
Cash equivalents are short-term, highly safe investments that a company can quickly turn into cash, such as Treasury bills, money-market accounts or very short-term bank deposits. Think of them like a spare set of ready cash in a high-quality savings jar that can be tapped immediately. Investors watch this balance because it shows how easily a company can cover bills, weather shocks, or seize sudden opportunities without selling long-term assets.
marketable securities financial
"$5.5 million in cash and cash equivalents, $0.3 million in restricted cash and $64.1 million in marketable securities"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
Earnings Snapshot
Net loss Q2 2026: $4.3 million · Guidance included
Quarter and six months ended June 30, 2026
Net loss Q2 2026
$4.3 million
Lower than $21.4 million in Q2 2025
Total operating expenses Q2 2026
$5.6 million
Lower than $23.4 million in Q2 2025
Non-GAAP net loss Q2 2026
$3.1 million
Lower than $19.0 million in Q2 2025
Guidance
Instil expects its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 will enable it to fund its operating plan beyond 2027.
FAQ
What was Instil Bio (TIL)'s cash position as of June 30, 2026?
Instil Bio held $69.9 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026, including $5.5 million in cash and cash equivalents and $64.1 million in marketable securities.
How long does Instil Bio (TIL) expect its cash to fund operations?
Instil Bio expects its $69.9 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 to fund its current operating plan beyond 2027, based on its existing projections.
What was Instil Bio (TIL)'s net loss and EPS for Q2 2026?
For the quarter ended June 30, 2026, Instil Bio reported a net loss of $4.3 million, or $0.63 per basic and diluted share, compared with a net loss of $21.4 million, or $3.24 per share, in Q2 2025.
How did Instil Bio (TIL)'s operating expenses change in Q2 2026?
Total operating expenses declined to $5.6 million in Q2 2026 from $23.4 million a year earlier, reflecting nil in-process R&D, lower research and development of $0.3 million, and reduced restructuring and impairment charges.
What are Instil Bio (TIL)'s non-GAAP net loss figures for Q2 2026?
Instil Bio reported non-GAAP net loss of $3.1 million, or $0.45 per basic and diluted share for Q2 2026, excluding non-cash stock-based compensation and restructuring and impairment charges from GAAP net loss.
Is Instil Bio (TIL) pursuing acquisitions or in-licensing opportunities?
Instil Bio stated it is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates, as part of its corporate strategy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2026
(Exact name of registrant as specified in its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
(972 ) 499-3350
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 13, 2026 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits | ||||||||
Exhibit No. | Description | |||||||
99.1 | Press release, dated August 13, 2026 | |||||||
104 | The cover page of this report has been formatted in Inline XBRL. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Instil Bio, Inc. | ||||||||||||||||||||
Dated: | By: | /s/ Sandeep Laumas, M.D. | ||||||||||||||||||
Sandeep Laumas, M.D. | ||||||||||||||||||||
Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer) | ||||||||||||||||||||
Instil Bio Reports Second Quarter 2026 Financial Results and
Provides Corporate Update
DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update.
Recent Highlights:
•Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.
•Cash position of approximately $69.9 million as of June 30, 2026 expected to fund current operating plan beyond 2027.
Second Quarter 2026 Financial and Operating Results:
As of June 30, 2026, Instil had cash, cash equivalents, restricted cash and marketable securities of $69.9 million, which consisted of $5.5 million in cash and cash equivalents, $0.3 million in restricted cash and $64.1 million in marketable securities, compared to $76.3 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, consisting of $6.6 million in cash and cash equivalents, $0.2 million in restricted cash, and $69.5 million in marketable securities. Instil expects that its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026 will enable it to fund its operating plan beyond 2027.
In-process research and development expenses were nil for the three and six months ended June 30, 2026, compared to $10.0 million for both the three and six months ended June 30, 2025.
Research and development expenses were $0.3 million and $0.9 million for the three and six months ended June 30, 2026, respectively, compared to $6.7 million and $12.1 million for the three and six months ended June 30, 2025, respectively.
General and administrative expenses were $5.1 million and $10.5 million for the three and six months ended June 30, 2026, respectively, compared to $6.2 million and $15.3 million for the three and six months ended June 30, 2025, respectively.
Restructuring and impairment charges, net were $0.2 million and $1.2 million for the three and six months ended June 30, 2026, respectively, compared to $0.5 million and $16.6 million for three and six months ended June 30, 2025, respectively.
Net loss per share, basic and diluted were $0.63 and $1.25 for the three and six months ended June 30, 2026, respectively, compared to $3.24 and $7.55 for the three and six months ended June 30, 2025, respectively. Non-GAAP net loss per share, basic and diluted, were $0.45 and $0.78 for the three and six months ended June 30, 2026, respectively, compared to $2.88 and $4.21 for the three and six months ended June 30, 2025, respectively.
Note Regarding Use of Non-GAAP Financial Measures
In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial
measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges, net. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.
About Instil Bio
Instil Bio, Inc. is a biotechnology company focused on identifying and advancing innovative therapeutics. For more information, visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “evaluating,” “focused,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil’s expectations regarding pursuing potential acquisitions, in-licensing and related opportunities; Instil’s expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to pursuing potential transactions to acquire companies or equity interests therein or in-license product candidates, and the sufficiency of Instil’s cash resources, as well as interest rates, inflation and other factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil’s plans and strategy, including those discussed in the section titled “Risk Factors” in Instil’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the SEC and Instil’s Annual Report on Form 10-K for the year ended December 31, 2025 filed on March 27, 2026, as well as Instil’s other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations:
1-972-499-3350
investorrelations@instilbio.com
www.instilbio.com
INSTIL BIO, INC.
SELECTED FINANCIAL DATA
Selected Condensed Consolidated Balance Sheet Data
(Unaudited; in thousands)
| June 30, 2026 | December 31, 2025 | ||||||||||
| Cash, cash equivalents, restricted cash and marketable securities | $ | 69,932 | $ | 76,295 | |||||||
| Total assets | $ | 197,712 | $ | 203,523 | |||||||
| Total liabilities | $ | 90,332 | $ | 89,657 | |||||||
| Total stockholders’ equity | $ | 107,380 | $ | 113,866 | |||||||
Condensed Consolidated Statements of Operations
(Unaudited; in thousands, except share and per share amounts)
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| June 30, | June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| In-process research and development | $ | — | $ | 10,000 | $ | — | $ | 10,000 | |||||||||||||||
| Research and development | 270 | 6,743 | 939 | 12,114 | |||||||||||||||||||
| General and administrative | 5,130 | 6,157 | 10,479 | 15,266 | |||||||||||||||||||
| Restructuring and impairment charges, net | 181 | 540 | 1,173 | 16,622 | |||||||||||||||||||
| Total operating expenses | 5,581 | 23,440 | 12,591 | 54,002 | |||||||||||||||||||
| Loss from operations | (5,581) | (23,440) | (12,591) | (54,002) | |||||||||||||||||||
| Interest income | 632 | 1,044 | 1,310 | 2,219 | |||||||||||||||||||
| Interest expense | (1,582) | (1,582) | (3,134) | (2,680) | |||||||||||||||||||
| Other rental income | 2,242 | 2,242 | 4,484 | 4,484 | |||||||||||||||||||
| Gain on contract termination | — | — | 1,620 | — | |||||||||||||||||||
| Other (expense) income, net | (10) | 342 | (192) | 385 | |||||||||||||||||||
| Net loss | $ | (4,299) | $ | (21,394) | $ | (8,503) | $ | (49,594) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.63) | $ | (3.24) | $ | (1.25) | $ | (7.55) | |||||||||||||||
| Weighted-average shares used in computing net loss per share, basic and diluted | 6,781,976 | 6,596,975 | 6,781,976 | 6,564,994 | |||||||||||||||||||
INSTIL BIO, INC.
Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share
(Unaudited; in thousands, except share and per share amounts)
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| June 30, | June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net loss | $ | (4,299) | $ | (21,394) | $ | (8,503) | $ | (49,594) | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Non-cash stock-based compensation expense | 1,036 | 1,824 | 2,021 | 5,319 | |||||||||||||||||||
| Restructuring and impairment charges, net | 181 | 540 | 1,173 | 16,622 | |||||||||||||||||||
| Non-GAAP net loss | $ | (3,082) | $ | (19,030) | $ | (5,309) | $ | (27,653) | |||||||||||||||
| Net loss per share, basic and diluted | $ | (0.63) | $ | (3.24) | $ | (1.25) | $ | (7.55) | |||||||||||||||
| Adjustments: | |||||||||||||||||||||||
| Non-cash stock-based compensation expense per share | 0.15 | 0.28 | 0.30 | 0.81 | |||||||||||||||||||
| Restructuring and impairment charges, net per share | 0.03 | 0.08 | 0.17 | 2.53 | |||||||||||||||||||
| Non-GAAP net loss per share, basic and diluted* | $ | (0.45) | $ | (2.88) | $ | (0.78) | $ | (4.21) | |||||||||||||||
| Weighted-average shares outstanding, basic and diluted | 6,781,976 | 6,596,975 | 6,781,976 | 6,564,994 | |||||||||||||||||||
* Non-GAAP net loss per share, basic and diluted may not total due to rounding.
###